Other Guidelines | Page 29 | European Cystic Fibrosis Society (ECFS)

People with cystic fibrosis-related diabetes do not have a lower exercise capacity compared to those without diabetes: data from an international multicenter study

A Study Characterizing Sweat Chloride after CFTR Modulators in People with Cystic Fibrosis

Are we missing Aspergillus in airway samples due to bacteria that may also be present?

Eruption of brown moles following Trikafta/Kaftrio treatment for cystic fibrosis

Elexacaftor-Tezacaftor-Ivacaftor (ETI) improve stomach, gullet, nose and throat symptoms in people with advanced CF

ivacaftor does not change gut bacteria, inflammation or pancreas function

Long-term health effects of real-world use of ivacaftor by people with cystic fibrosis who have non-G551D-CFTR gating mutations

High blood eosinophil counts are linked with worse symptoms in adults with cystic fibrosis

Club cell secretory protein is reduced in children with cystic fibrosis who have severe lung disease

CFTR modulators: A case where Triple therapy induced rash resolved on its own, without stopping the drug

first
previous
…
25
26
27
28
29
30
31
32
33
…
next
last